{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
olmesartan
to a specific field?
Olmesartan Lactone Impurity (Olmesartan EP Impurity B) is a cyclic ester impurity in commercial preparations of olmesartan medoxomil. Olmesartan medoxomil is an angiotensin II receptor antagonist, which is indicated for the treatment of hypertension.
Status:
Possibly Marketed Outside US
Source:
NCT02816567: Phase 4 Interventional Unknown status Patients Ongoing Elective Abdominal Laparoscopy
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
US Approved Rx
(2013)
First approved in 1958
Class:
MIXTURE
Status:
Investigational
Source:
NCT03830736: Not Applicable Interventional Completed Postprandial Glucose Regulation
(2019)
Source URL:
Class:
PROTEIN
